Searching for the field study fenofibrate diabetic retinopathy doi usually means one of two things: you need the exact citation for a paper, or you want to know whether the trial matters for your own eyes. This guide covers both. The FIELD study, short for Fenofibrate Intervention and Event Lowering in Diabetes, enrolled 9,795 adults with type 2 diabetes and tested whether a daily fenofibrate capsule could prevent cardiovascular events. Its eye findings became the real surprise.
Searching for the field study fenofibrate diabetic retinopathy doi usually means one of two things: you need the exact citation for a paper, or you want to know whether the trial matters for your own eyes. This guide covers both. The FIELD study, short for Fenofibrate Intervention and Event Lowering in Diabetes, enrolled 9,795 adults with type 2 diabetes and tested whether a daily fenofibrate capsule could prevent cardiovascular events. Its eye findings became the real surprise.
The main results appeared in The Lancet in 2005 under the DOI 10.1016/S0140-6736(05)67667-2. The retinopathy findings followed in a 2007 Lancet paper by Keech and colleagues, DOI 10.1016/S0140-6736(07)61607-9. You can paste either string after https://doi.org/ to reach the publisher page. Always confirm a DOI by opening it, because one mistyped character sends you to the wrong paper, and citation managers sometimes copy identifiers with trailing punctuation attached.
Diabetic retinopathy is damage to the tiny blood vessels in the retina, and it is a leading cause of preventable vision loss among working-age adults in the United States. About one in three people with diabetes shows some sign of it. Early disease causes no symptoms at all, which is why many people only learn about it after the damage is advanced. Any treatment that slows the process, even modestly, deserves a close look.
Before getting into numbers, a note on scope. This article is educational and is not medical advice. Fenofibrate is FDA-approved to lower triglycerides and cholesterol, not to treat retinopathy, so using it for eye protection is a conversation to have with your physician and eye specialist. We will explain what the trials showed, what they did not show, and how the evidence connects to everyday diabetes care and decision making.
Diabetes care spans many topics, and readers arrive from many directions. Some come from searches such as diabeto, types of diabetes, or the difference between type 1 and type 2 diabetes. Others are managing foot health and comparing diabetic shoes, or planning snacks for diabetics. Retinopathy ties into all of it, because the same glucose, blood pressure, and lipid control that protects your feet and kidneys also protects the small vessels in your eyes.
The FIELD study is also a useful lesson in how to read research. Its primary goal, reducing coronary events, was not met in a statistically significant way. Yet the secondary and tertiary results on laser eye treatment drew attention for years afterward. Understanding the difference between a primary and a secondary outcome helps you avoid both overhyping and dismissing a result, which is a skill that applies to nearly every headline about diabetes research you will encounter.
Here is the roadmap. We start with key numbers, then break down the trial design, what the retinopathy data showed, and how later studies such as ACCORD Eye and LENS built on it. After that we cover risks, practical steps, and the symptom and screening knowledge, from diabetic ketoacidosis symptoms to signs of gestational diabetes, that every person living with diabetes should keep close at hand.
FIELD was a randomized, double-blind, placebo-controlled trial in Australia, New Zealand, and Finland. Adults with type 2 diabetes received 200 mg of micronized fenofibrate daily or placebo for a median of five years, with cardiovascular events as the primary goal.
The 2005 primary paper uses DOI 10.1016/S0140-6736(05)67667-2. The 2007 retinopathy paper, Lancet 370:1687-1697, uses DOI 10.1016/S0140-6736(07)61607-9. Resolve either by adding it to https://doi.org/ and confirm the title.
Fenofibrate cut the need for a first laser treatment by 31 percent, with 164 treated patients needing laser versus 238 on placebo. The effect covered both macular edema and proliferative disease, though it was a tertiary outcome.
The primary cardiovascular result was not statistically significant, retinopathy was not the main endpoint, and more placebo patients started statins. Laser need also depends on clinician judgment, so results should be read as supportive rather than definitive.
FIELD recruited participants across Australia, New Zealand, and Finland between 1998 and 2000. Eligible adults were 50 to 75 years old, had type 2 diabetes, and were not taking a statin at entry. Most had total cholesterol between 116 and 251 mg/dL and either a total-to-HDL cholesterol ratio of 4.0 or higher or triglycerides between 89 and 443 mg/dL. Roughly 22 percent already had cardiovascular disease, so the group mixed primary and secondary prevention.
Participants were randomized to 200 mg of micronized fenofibrate daily or matching placebo, then followed for a median of five years. After a run-in phase, 4,895 people received fenofibrate and 4,900 received placebo. Because doctors could add statins when clinically needed, more placebo patients ended up on statins than fenofibrate patients. That drop-in therapy slightly blurred the comparison and is one reason the headline cardiovascular result looked weaker than investigators expected.
The primary outcome was coronary heart disease death or nonfatal heart attack. Fenofibrate lowered it by 11 percent, a result that did not reach statistical significance. Total cardiovascular events fell by 11 percent and did reach significance, driven by fewer nonfatal heart attacks and revascularization procedures. These mixed signals prompted researchers to look carefully at microvascular outcomes, where fibrates were thought to have a different kind of influence than on large artery disease.
Microvascular endpoints were pre-specified as tertiary outcomes. Fenofibrate reduced the need for first laser treatment for retinopathy, with 164 of 4,895 treated patients needing it versus 238 of 4,900 on placebo. That is a 31 percent relative reduction, with a hazard ratio of 0.69. Laser treatment for macular edema and for proliferative retinopathy both fell. Because laser follows a detected problem, regular screening through a diabetic eye exam remains essential.
An ophthalmology substudy followed 1,012 participants with retinal photographs graded on the ETDRS scale. Across the whole substudy, two-step progression was lower with fenofibrate, roughly 9.6 versus 15.9 percent, but the difference was not statistically significant. Among the smaller group who already had retinopathy at baseline, progression was far lower, about 3.1 versus 14.6 percent. Check the exact figures in the paper before quoting them in academic work.
Notice what the design implies. Retinopathy outcomes were not the primary goal, the substudy was modest in size, and the laser endpoint reflects decisions made by many different ophthalmologists. These are real limitations. Still, laser treatment is a hard, patient-relevant event rather than a lab value, and the effect appeared across thousands of participants. That is why the result has been discussed in guideline conversations for nearly two decades and keeps appearing in reviews.
Another intriguing detail is that the eye benefit did not track lipid changes closely. Fenofibrate activates PPAR-alpha, a receptor that influences inflammation, oxidative stress, and blood-retinal barrier integrity. Researchers think these effects, rather than triglyceride lowering alone, may explain the retinal signal. That hypothesis remains under investigation, and it is one reason newer trials test fenofibrate directly in people with eye disease rather than only in people with abnormal lipid levels.
In type 1 diabetes, retinopathy rarely appears in the first few years, but risk climbs steadily. Roughly 90 percent of people develop some retinal changes within 20 years. The Diabetes Control and Complications Trial showed that intensive insulin therapy cut new retinopathy by 76 percent. Because onset is autoimmune and usually early in life, cumulative exposure to high glucose is long, so consistent screening matters even when vision feels perfect.
The FIELD study enrolled only adults with type 2 diabetes, so its fenofibrate results do not directly apply to type 1. The LENS trial included a mix of participants, and data in type 1 remain limited. Anyone with type 1 diabetes considering fenofibrate should talk with an endocrinologist and retina specialist, and should always know the diabetic ketoacidosis symptoms, which are the more immediate danger.
When comparing type 1 diabetes vs type 2, remember the core difference: type 1 involves little or no insulin production, while type 2 involves insulin resistance with declining production. Type 2 accounts for about 90 to 95 percent of US cases. Because it can go undetected for years, roughly one in five people already show retinopathy at diagnosis, which makes an eye exam at the time of diagnosis essential.
FIELD, ACCORD Eye, and LENS all focused largely on type 2, which is why most fenofibrate evidence applies there. Remission through weight loss is possible for some, which answers the common question can diabetes be reversed. Still, retinal screening should continue after remission because past high glucose leaves lasting vascular effects. Treat remission as a reason to keep monitoring, not a reason to stop.
Gestational diabetes develops during pregnancy, usually appears between 24 and 28 weeks, and affects about 2 to 10 percent of US pregnancies. Signs of gestational diabetes are often absent, though some women notice excessive thirst, frequent urination, fatigue, or blurred vision. Screening with a glucose challenge test is routine for this reason. Gestational diabetes by itself seldom causes retinopathy because exposure to high glucose is relatively short.
Women with type 1 or type 2 diabetes before pregnancy face a different situation. Pregnancy can accelerate retinopathy, so they should have a dilated eye exam before conception or in the first trimester, then follow-up exams as their eye doctor advises. Fenofibrate is generally avoided during pregnancy, so any eye-protection plan should be revisited with your care team when planning a family.
Across FIELD, ACCORD Eye, and LENS, fenofibrate slowed retinopathy progression by roughly a quarter to two-fifths, but always on top of good glucose and blood pressure control. No trial showed it can replace those basics or restore vision already lost.
The ACCORD Eye substudy, published in the New England Journal of Medicine in 2010 under DOI 10.1056/NEJMoa1001288, tested fenofibrate added to simvastatin in 2,856 participants with type 2 diabetes at high cardiovascular risk. After four years, retinopathy progression occurred in 6.5 percent of the fenofibrate group versus 10.2 percent of the placebo group, an adjusted reduction of about 40 percent. The finding gave FIELD's signal a second, independent confirmation.
ACCORD's main lipid trial found no overall cardiovascular benefit from adding fenofibrate to a statin, so it did not change cardiology guidelines. Intensive glucose control also cut eye progression by about a third in ACCORD Eye, which shows that glucose, lipids, and blood pressure all interact. A fair reading is that fenofibrate offered extra protection beyond good glucose control, not a substitute for it, and that no single factor explains who progresses.
The LENS trial in Scotland, reported in NEJM Evidence in 2024, enrolled about 1,150 adults with early nonproliferative retinopathy or maculopathy. They received 145 mg of fenofibrate or placebo for a median of roughly four years. Progression to referable disease or need for treatment occurred about 27 percent less often with fenofibrate. LENS mattered because it targeted eye disease directly rather than lipid abnormalities, so the benefit did not depend on having high triglycerides.
Other work continues. The DRCR Retina Network has been running Protocol AF, which tests fenofibrate for people with nonproliferative disease, and observational cohorts from several countries have reported similar protective trends. Until more results arrive, professional guidance such as the American Diabetes Association Standards of Care treats fenofibrate as an option worth discussing, particularly for patients with existing retinopathy and lipid abnormalities, rather than as a universal recommendation for everyone with diabetes.
People often ask whether diabetes can be reversed and whether retinopathy can heal. Type 2 diabetes can go into remission with substantial weight loss, as in the DiRECT trial, where 46 percent of participants reached remission at one year. Established retinal damage, however, rarely reverses. The realistic goals are slowing or halting progression and treating sight-threatening disease early with anti-VEGF injections, laser therapy, or surgery when needed.
Retinopathy risk also differs by diabetes type. After 20 years, nearly all people with type 1 diabetes and more than 60 percent with type 2 show some retinopathy. Pregnancy can accelerate eye changes, so anyone with preexisting diabetes who becomes pregnant needs an early eye exam. Gestational diabetes alone does not typically cause retinopathy, but it raises later type 2 risk, which is a reason to keep screening on your calendar for decades.
Putting the three trials together, the pattern is consistent: fenofibrate reduced eye-related events by roughly a quarter to two-fifths in different populations. Consistency across designs raises confidence, yet effect sizes vary, follow-up is limited to four or five years, and none of the trials ran long enough to show whether vision itself improves. That is why clinicians frame fenofibrate as an adjunct, layered over glucose and blood pressure management and regular retinal screening.
In FIELD, fenofibrate was generally well tolerated, but there were small excesses of pancreatitis (0.8 versus 0.5 percent) and pulmonary embolism (1.1 versus 0.7 percent). Fenofibrate can raise serum creatinine reversibly, so doctors check kidney function before and during treatment and adjust the dose accordingly. It is not recommended with severe kidney disease or active gallbladder disease. Muscle symptoms are uncommon but should always be reported promptly.
Pregnancy and breastfeeding deserve special mention. Fenofibrate is generally avoided in both, so women who may become pregnant should raise the topic early. It can also strengthen the effect of warfarin, meaning clotting tests need closer tracking. Bring a complete medication and supplement list to every visit, because interactions are far easier to prevent than to treat after a problem develops.
Eye protection starts with glucose. The Diabetes Control and Complications Trial showed that intensive therapy cut the onset of retinopathy by 76 percent in type 1 diabetes, and the UKPDS found about a 25 percent reduction in microvascular complications with tighter control in type 2. One caution: very rapid A1C improvement can temporarily worsen retinopathy, so people with existing eye disease should have an exam before and during major treatment changes.
Diabetic ketoacidosis symptoms are an emergency that every person with diabetes should recognize. They include intense thirst, frequent urination, nausea and vomiting, abdominal pain, fruity-smelling breath, rapid deep breathing, confusion, and unusual fatigue. DKA is most common in type 1 diabetes but can occur in type 2. Blood glucose is often above 250 mg/dL, and ketones in urine or blood confirm the danger. Call 911 or go to an emergency room.
Signs of gestational diabetes are often subtle: increased thirst, frequent urination, fatigue, or blurred vision. Many women have no signs at all, which is why a glucose challenge screen at 24 to 28 weeks is routine. Blurred vision during pregnancy deserves attention but has many causes, so report it. After delivery, retest at 4 to 12 weeks and then every one to three years, because gestational diabetes raises long-term type 2 risk.
Microvascular damage rarely stays in one place. Retinopathy often travels with neuropathy and kidney disease, so an eye diagnosis is a prompt to inspect your feet daily. Well-fitted diabetic socks with seamless toes and moisture-wicking fabric reduce friction, and Medicare Part B may cover one pair of therapeutic shoes per year for qualifying patients with a physician certification. Ask your podiatrist about the exact requirements.
Sudden floaters, a curtain across your vision, flashes of light, or abrupt vision loss can signal vitreous hemorrhage or retinal detachment and need same-day eye care. Do not wait for your next annual visit. Gradual blurring, trouble with night vision, or dark patches are also reasons to book an appointment. Remember that the earliest stages of retinopathy produce no symptoms, so symptom-based screening alone will always miss early disease.
If you need the citation for a paper, class, or clinic handout, build it from the DOI. Open https://doi.org/ followed by the identifier, confirm the title, authors, journal, and year, then copy the format your style guide requires. For FIELD retinopathy, cite Keech et al., Lancet 2007;370:1687-1697. Cite the 2005 paper separately for the primary cardiovascular findings so readers do not confuse the two publications.
Bring a short list to your next visit: your latest A1C, blood pressure, lipid panel, and the date of your last dilated eye exam. Ask whether your retinopathy stage and triglyceride level make you a candidate for fenofibrate, what kidney tests you need, and how it interacts with statins and blood thinners such as warfarin. Write down the answers so you can share them with your eye specialist afterward.
Common targets include an A1C below 7 percent for many adults, blood pressure below 130/80 mmHg, and LDL cholesterol below 100 mg/dL, or below 70 mg/dL with cardiovascular disease. Your targets may differ, especially if you are older or prone to low blood sugar. Keep a simple log for two weeks before your appointment, because trends reveal far more than a single reading and help your doctor make safer adjustments.
Food choices support all of it. Smart snacks for diabetics pair fiber or protein with a small portion of carbohydrate, such as apple slices with peanut butter, plain Greek yogurt with berries, a small handful of almonds, or hummus with raw vegetables. Aim for roughly 15 to 20 grams of carbohydrate per snack unless your plan says otherwise. For something sweet, try homemade diabetic desserts built on berries and dark chocolate.
Representation helps younger patients and their families. In 2025 Mattel released a type 1 diabetes Barbie doll wearing a continuous glucose monitor and insulin pump, which gave many families an easy way to start conversations about daily care. Children with type 1 diabetes should begin eye screening three to five years after diagnosis once they are age 11 or older, so the toy is a nice reminder that screening starts early.
Screening schedules vary by type. Adults with type 1 diabetes should have a dilated exam within five years of diagnosis, then at least yearly. Adults with type 2 should be examined at diagnosis, since onset is often years earlier. If exams are normal and glucose is well controlled, your doctor may extend the interval to one or two years. FDA-cleared AI retinal cameras in primary care are convenient, but abnormal results still need an ophthalmologist.
If you are studying this material for a nursing, pharmacy, or certification exam, practice questions help lock it in. Focus on trial names, key percentages, and the difference between primary and secondary outcomes. Quiz yourself on DKA symptoms, hypoglycemia, and screening intervals, then review every miss. Short, repeated sessions beat marathon cramming, and our free blood sugar management quizzes are a good place to begin before moving to the complications questions.